Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its...
Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its...
Teva Entered Into An Agreement With JKI Co. Established By The Fund Managed And Operated By Private Equity Firm J-Will Partners Co., Through Which JKI Will Acquire Teva-Takeda; The Agreement Is Aligned With Teva's Pivot To Growth Strategy To Focus Its Business; No Financial Terms Disclosed
梯瓦与由股权投资公司J-Will Partners管理和运营的基金设立的JKI公司达成协议，通过该协议，JKI将收购梯瓦-武田；该协议符合梯瓦转向增长策略以聚焦其业务；未透露任何财务条款。
- Teva entered into an agreement with JKI Co., Ltd. ("JKI") established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will"), through which JKI will acquire Teva-Takeda
- The agreement is aligned with Teva's Pivot to Growth strategy to focus its business
- The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market
- 梯瓦与由股权投资公司J-Will Partners管理和运营的基金设立的JKI公司达成协议，通过该协议，JKI将收购梯瓦-武田。
- 协议与梯瓦的增长策略相一致，以专注其业务。
- 预计剥离梯瓦在日本的业务创业公司梯瓦-武田，其中包括仿制药和传统产品，将使梯瓦能够专注于将其创新药品带入日本市场。
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
2024年12月05日，以色列特拉维夫，今日，梯瓦制药工业有限公司（纽交所和特拉维夫证券交易所：TEVA）宣布，已与由J-Will管理和运营的基金设立的JKI达成协议，根据该协议，梯瓦武田制药有限公司及其全资子公司梯瓦武田药品有限公司的所有股份将被转让给JKI。
Teva recently communicated that it was open to exploring new strategic approaches in Japan, including a possible divestment of its Teva-Takeda business venture, in alignment with its Pivot to Growth strategy. The divestment will allow Teva to focus on its innovative medicines business in Japan.
梯瓦最近表示，愿意探索在日本的新战略方法，包括可能剥离其梯瓦-武田业务创业公司，以与其增长策略保持一致。剥离将使梯瓦能够在日本专注于其创新药品业务。
Teva expects the divestiture to be completed by 1 April, 2025, subject to standard closing conditions, including obtaining required regulatory approvals. All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.
梯瓦预计剥离将于2025年4月1日完成，视情况需满足标准的闭幕条件，包括获得必要的监管批准。日本业务创业公司的所有员工将继续受雇，受协议条款约束。
